Merck
  • Serum plant sterols, cholestanol, and cholesterol precursors associate with histological liver injury in pediatric onset intestinal failure.

Serum plant sterols, cholestanol, and cholesterol precursors associate with histological liver injury in pediatric onset intestinal failure.

The American journal of clinical nutrition (2014-08-08)
Annika Mutanen, Markku J Nissinen, Jouko Lohi, Päivi Heikkilä, Helena Gylling, Mikko P Pakarinen
要旨

Increased serum concentrations of plant sterols, including stigmasterol, during parenteral nutrition (PN) have been linked with serum biochemical signs of intestinal failure-associated liver disease (IFALD), whereas clinical data on their correlation to histologic liver injury have been limited. We studied interrelations between serum noncholesterol sterols and histologic liver injury in pediatric-onset intestinal failure (IF). Serum plant sterols (stigmasterol, avenasterol, sitosterol, and campesterol), cholestanol, and cholesterol precursors (cholestenol, lathosterol, and desmosterol) were measured in 50 IF patients at a median age 7.3 y and in 86 matched controls. Forty patients underwent liver biopsies. Sixteen patients had been receiving PN for 45 mo, and 34 patients had received PN for 9.1 mo but had not received PN for 5.4 y. Serum plant sterols were higher in patients who were currently receiving PN than in controls and were related to conjugated bilirubin (r = 0.799-0.541, P < 0.05). During PN, the ratio of serum stigmasterol to cholesterol was 3.3-fold higher in patients with portal inflammation, and the ratio of avenasterol to cholesterol was 3.9-fold higher in patients with cholestasis (P < 0.05 for both). Ratios of stigmasterol and avenasterol to cholesterol were correlated with portal inflammation (r = 0.549-0.510, P < 0.05), cholestasis (r = 0.501-0.491, P = 0.048-0.053), and serum bile acids (r = 0.591-0.608, P < 0.05). The median (IQR) ratio of serum cholestanol to cholesterol was higher during (269 100× μg/mg cholesterol; 203-402 100× μg/mg cholesterol) than after (175 100× μg/mg cholesterol; 156-206 100× μg/mg cholesterol; P < 0.001) weaning off PN and was correlated with cholestasis (r = 0.428), portal inflammation (r = 0.511), and fibrosis (r = 0.323, P < 0.05 for all). After weaning off PN, ratios of cholestenol and lathosterol to cholesterol were >2-fold higher in patients with persistent liver steatosis than in those without steatosis or controls (P < 0.01 for all), whereas lathosterol was correlated with the steatosis grade (r = 0.320, P < 0.050). Increased serum stigmasterol and avenasterol concentrations parallel the portal inflammation and cholestasis during PN, thereby reinforcing their contribution to IFALD. A bile acid malabsorption-driven increase in cholesterol synthesis underpins persistent liver steatosis after weaning off PN. Serum cholestanol reflects liver injury in IF patients.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
コレステロール, Sigma Grade, ≥99%
Sigma-Aldrich
コレステロール, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
コレステロール, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
スチグマステロール, ~95%
SAFC
コレステロール、植物由来, SyntheChol®
Sigma-Aldrich
SyntheChol® NS0サプリメント, 500 ×, synthetic cholesterol, animal component-free, sterile-filtered, aqueous solution, suitable for cell culture
Supelco
コレステロール 溶液, certified reference material, 10 mg/mL in chloroform
Sigma-Aldrich
5α-コレスタン-3β-オール, ≥95%
Sigma-Aldrich
コレステロール, tested according to Ph. Eur.
Sigma-Aldrich
5β-コレスタン-3α-オール, ≥95%
Supelco
スチグマステロール, certified reference material, 10 mg/mL in chloroform
Supelco
(+)-ジヒドロコレステロール 溶液, certified reference material, 10 mg/mL in chloroform
Sigma-Aldrich
コプロスタン-3-オール, ≥98%
Avanti
5β,6β-epoxycholestanol-d7, Avanti Polar Lipids